BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhang B, Wang L, Zhang Q, Yan Y, Jiang H, Hu R, Zhou X, Liu X, Feng J, Lin N. The Ibr-7 derivative of ibrutinib exhibits enhanced cytotoxicity against non-small cell lung cancer cells via targeting of mTORC1/S6 signaling. Mol Oncol 2019;13:946-58. [PMID: 30663221 DOI: 10.1002/1878-0261.12454] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Szklener K, Michalski A, Żak K, Piwoński M, Mańdziuk S. Ibrutinib in the Treatment of Solid Tumors: Current State of Knowledge and Future Directions. Cells 2022;11:1338. [DOI: 10.3390/cells11081338] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
2 Zhang B, Yan YY, Gu YQ, Teng F, Lin X, Zhou XL, Che JX, Dong XW, Zhou LX, Lin NM. Inhibition of TRIM32 by ibr-7 treatment sensitizes pancreatic cancer cells to gemcitabine via mTOR/p70S6K pathway. J Cell Mol Med 2021. [PMID: 34921503 DOI: 10.1111/jcmm.17109] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
3 Wu J, Zhou J, Xu Q, Foley R, Guo J, Zhang X, Tian C, Mu M, Xing Y, Liu Y, Wang X, Hu D. Identification of Key Genes Driving Tumor Associated Macrophage Migration and Polarization Based on Immune Fingerprints of Lung Adenocarcinoma. Front Cell Dev Biol 2021;9:751800. [PMID: 34805160 DOI: 10.3389/fcell.2021.751800] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Liu SC, Wu YC, Huang CM, Hsieh MS, Huang TY, Huang CS, Hsu TN, Huang MS, Lee WH, Yeh CT, Lin CS. Inhibition of Bruton's tyrosine kinase as a therapeutic strategy for chemoresistant oral squamous cell carcinoma and potential suppression of cancer stemness. Oncogenesis 2021;10:20. [PMID: 33640903 DOI: 10.1038/s41389-021-00308-z] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
5 Tan B, Dong R, Zhang B, Yan Y, Li Q, Wang F, Lin N. The Ibr-7 derivative of ibrutinib radiosensitizes pancreatic cancer cells by downregulating p-EGFR. Cancer Cell Int 2020;20:458. [PMID: 32963499 DOI: 10.1186/s12935-020-01548-6] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
6 Bi KW, Wei XG, Qin XX, Li B. BTK Has Potential to Be a Prognostic Factor for Lung Adenocarcinoma and an Indicator for Tumor Microenvironment Remodeling: A Study Based on TCGA Data Mining. Front Oncol 2020;10:424. [PMID: 32351880 DOI: 10.3389/fonc.2020.00424] [Cited by in Crossref: 21] [Cited by in F6Publishing: 51] [Article Influence: 10.5] [Reference Citation Analysis]